Joe:
Ha-yup! Like those numbers. Can u tell me which brokers are rec. der buys?
FYI, I know this is old news, but it slipped right on past me..
Tuesday February 18 2:00 PM EDT
BioSource International Describes New Product
Line at Cruttenden Growth Stock Conference
LAGUNA NIGUEL, Calif., Feb. 18 /PRNewswire/ -- At the Cruttenden Growth Stock
Conference today, James C. Chamberlain of BioSource International, Inc., (Nasdaq:
BI0I), will discuss the Company's plans to introduce a line of test kit products, named
Genexpress(TM), used in conjunction with Polymerase Chain Reaction techniques. The
kits, which represent a new market area for BioSource, will be formally introduced at a
trade exhibition next week in San Francisco.
The combination of Polymerase Chain Reaction (PCR) amplification and Genexpress
technology is used to quantify gene sequences that are normally unmeasurable in blood
serum or samples. Researchers use the technique to aid in detection of gene disorders
and to monitor disease progression.
"These new products mark our entry into molecular diagnostic products," said James
H. Chamberlain, chairman, president and chief executive officer of BioSource
International. "Additionally, they are the first outcomes of collaborative research
agreements established last year with University research centers in Texas and West
Virginia, validating our approach to cooperative research with the academic
community."
BioSource International, Inc. is a Camarillo, Calif., based supplier of immunological
reagents and tests kits used in biomedical research. The Company offers more than
1,300 products, including recombinant proteins, monoclonal antibodies and ELISA
assay kits to a variety of antigens, and custom DNA segments (oligonucleotides). For
the year ended December 31, 1995, BioSource reported earnings of $1.16 million or
$.20 per share, on revenues of $8.6 million. On June 5, 1996, the Company completed
the acquisition of all of the assets related to the in vitro business Medgenix Diagnostics,
S.A., a Belgian company and formed a wholly-owned subsidiary, BioSource Europe,
S.A., which holds all of the assets in obligations acquired in the transaction.
This News Release may contain forward-looking statements that involve risks and
uncertainties, including risks associated with regulatory approvals and other risks
described from time to time in reports filed by BioSource with the Securities and
Exchange Commission, including its most recently filed Annual Report on Form 10-K.
SOURCE BioSource International, Inc.
Hot DAWG! |
